Articles related to ANTIDEPRESSANTS

Explore how a paradigm shift from monoamine to GABAergic systems could offer new, more effective treatments for major depressive disorder; the latest review discusses the unmet needs and the promising potential of NAS GABAA receptor PAMs.

Discover the implications of a newly identified depression subtype, “cognitive biotype,” which not only presents with significant cognitive impairments but also shows resistance to standard antidepressant treatments.

Discover the advancements in MDD pharmacotherapy that promise to expand treatment options and address unmet needs.

A recent study on bipolar I depression patients found that extended antidepressant maintenance for 52 weeks did not significantly prevent mood episode relapses compared to an 8-week regimen.

The study on the use of subcutaneous racemic ketamine in treatment-resistant depression underscores the significance of a flexible, individualized dosing approach over a 4-week course.

Explore the results of this study, which shed light on the underreported and frequently misunderstood phenomena of “brain zaps” during antidepressant withdrawal and its effects on medicine use and quality of life.